Risk of infection in patients with hematological malignancies receiving CAR T-cell therapy: systematic review and meta-analysis

Chimeric antigen receptor (CAR) T-cell therapy has emerged as a promising treatment option for relapsed or refractory B-cell malignancies and multiple myeloma. Underlying and treatment-related may contribute to the development of infectious complications. We conducted a systematic review and meta-analysis on the incidence of overall and severe (grade ≥3) infection in patients with hematological malignancies receiving CAR T-cells. Secondary outcomes included the specific rates of bacterial, viral and invasive fungal infection (IFI), and infection-related mortality. PubMed, Embase and Web of Science databases were searched from inception to 27 May 2022. Sensitivity analysis were performed according to the type of malignancy and study design (randomized clinical trials [RCTs] or observational studies). Forty-five studies (34 RCTs) comprising 3,591 patients were included. The pooled incidence rates of overall and severe infection were 33.8% (I2 = 96.31%) and 16.2% (I2 = 74.41%). The respiratory tract was the most common site of infection. Most events were bacterial or viral, whereas the occurrence of IFI was rare. The pooled attributable mortality was 1.8% (I2 = 43.44%). Infection is a frequent adverse event in patients receiving CAR T-cell therapy. Further research should address specific risk factors in this population.</p

Therapeutic measures and outcome of patients admitted to medical vs surgical wards.

<p>Therapeutic measures and outcome of patients admitted to medical vs surgical wards.</p

Comparison of the main demographic and clinical characteristics between patients admitted to surgical and medical wards.

<p>Comparison of the main demographic and clinical characteristics between patients admitted to surgical and medical wards.</p

Multivariate logistic regression analysis of prognostic factors associated with 30-day mortality.

<p>Multivariate logistic regression analysis of prognostic factors associated with 30-day mortality.</p

DataSheet1_Impact of polymorphisms in genes orchestrating innate immune responses on replication kinetics of Torque teno virus after kidney transplantation.PDF

Background: Torque teno virus (TTV) DNAemia has been proposed as a surrogate marker of immunosuppression after kidney transplantation (KT), under the assumption that the control of viral replication is mainly exerted by T-cell-mediated immunity. However, Tthe impact on post-transplant TTV kinetics of single genetic polymorphisms (SNPs) in genes orchestrating innate responses remains unknown. We aimed to characterize the potential association between 14 of these SNPs and TTV DNA levels in a single-center cohort of KT recipients.Methods: Plasma TTV DNAemia was quantified by real-time PCR in 221 KT recipients before transplantation (baseline) and regularly through the first 12 post-transplant months. We performed genotyping of the following SNPs: CTLA4 (rs5742909, rs231775), TLR3 (rs3775291), TLR9 (rs5743836, rs352139), CD209 (rs735240, rs4804803), IFNL3 (rs12979860, rs8099917), TNF (rs1800629), IL10 (rs1878672, rs1800872), IL12B (rs3212227) and IL17A (rs2275913).Results: The presence of the minor G allele of CD209 (rs4804803) in the homozygous state was associated with undetectable TTV DNAemia at the pre-transplant assessment (adjusted odds ratio: 36.96; 95% confidence interval: 4.72–289.67; p-value = 0.001). After applying correction for multiple comparisons, no significant differences across SNP genotypes were observed for any of the variables of post-transplant TTV DNAemia analyzed (mean and peak values, areas under the curve during discrete periods, or absolute increments from baseline to day 15 and months 1, 3, 6 and 12 after transplantation).Conclusion: The minor G allele of CD209 (rs4804803) seems to exert a recessive protective effect against TTV infection in non-immunocompromised patients. However, no associations were observed between the SNPs analyzed and post-transplant kinetics of TTV DNAemia. These negative results would suggest that post-transplant TTV replication is mainly influenced by immunosuppressive therapy rather than by underlying genetic predisposition, reinforcing its clinical application as a biomarker of adaptive immunity.</p

Sources of candidemia and <i>Candida</i> species according to statin groups.

*<p>The site of acquisition was not known in 2 patients.</p

Clinical characteristics of patients by statin group.

<p>Clinical characteristics of patients by statin group.</p

Univariate analysis of factors associated with 30-day mortality in medical and surgical wards.

<p>Univariate analysis of factors associated with 30-day mortality in medical and surgical wards.</p

Treatments and clinical outcomes of patients by statin groups.

<p>Treatments and clinical outcomes of patients by statin groups.</p